Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Completed 4Terminated 2Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1CNS 1

Conditions

Neuroblastoma 1Neoplasm Metastasis 1Melanoma 1Kidney Neoplasms 1

Interventions

Cyclophosphamide 98pembrolizumab 85Gemcitabine 81Carboplatin 62fludarabine 61Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 49Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 33Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26Pemetrexed 25atezolizumab 24Oxaliplatin 24Capecitabine 24fludarabine phosphate 22Filgrastim 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Terminated × Interleukin-12 × Clear all
NCT01457131 2019-01-08

Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
2 enrolled
DermatologicGenitourinary

Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT00054405 2013-04-09

Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

National Cancer Institute (NCI)

Phase 1 Terminated
40 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡